Monson Jonathan, Senior Vice President, Global Controller, and Chief Accounting Officer at Boston Scientific (BSX), has demonstrated a consistent pattern of selling activity in the company’s stock, with no recorded purchases across 24 transactions disclosed in SEC Form 4 filings. All trades involve BSX shares, with sales totaling $328,880.36 in value since February 2024. The transactions, executed under code "F" (indicating open-market or privately negotiated sales), show a steady cadence, with notable sales occurring in February 2026—$32,881.20 on February 16, $35,123.10 on February 14, and $58,887.24 on February 13. Earlier sales include $42,470.76 on February 12, 2026, and $55,656.48 on August 2, 2025, with smaller dispositions in February 2024 ranging from $16,981.56 to $32,183.60.
The filings reveal no recent buying activity, reinforcing a clear divestment trend. While some transactions, such as those marked with code "A" (award or grant of securities), show no monetary value—likely representing equity awards—the overall data points to a focus on liquidation rather than accumulation. The absence of purchases and the recurring sales suggest a deliberate reduction in Monson’s BSX holdings over time, though the reasons remain undisclosed in the filings. The transactions, spaced across multiple years, do not indicate urgency but rather a methodical unwinding of positions.
AI-assisted summary